Compare · MNMD vs RLX
MNMD vs RLX
Side-by-side comparison of Mind Medicine (MindMed) Inc. (MNMD) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MNMD and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $3.14B, about 7.2x MNMD ($438.1M).
- Over the past year, MNMD is up 96.1% and RLX is down 3.3% - MNMD leads by 99.5 points.
- RLX has hit the wire 3 times in the past 4 weeks while MNMD has been quiet.
- MNMD has more recent analyst coverage (16 ratings vs 2 for RLX).
- Company
- Mind Medicine (MindMed) Inc.
- RLX Technology Inc.
- Price
- $15.01+0.84%
- $2.04-1.93%
- Market cap
- $438.1M
- $3.14B
- 1M return
- +19.56%
- -5.35%
- 1Y return
- +96.14%
- -3.33%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 3
- Recent ratings
- 16
- 2
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest MNMD
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Chief Legal Officer Sullivan Mark sold $148,244 worth of shares (11,276 units at $13.15), decreasing direct ownership by 4% to 282,576 units (SEC Form 4)
- Chief Executive Officer Barrow Robert sold $339,072 worth of shares (25,791 units at $13.15), decreasing direct ownership by 3% to 778,477 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel sold $73,623 worth of shares (5,600 units at $13.15), decreasing direct ownership by 1% to 425,025 units (SEC Form 4)
- SEC Form 144 filed by Mind Medicine (MindMed) Inc.
- MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
- MindMed Announces New Employee Inducement Grant
- MindMed Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate
- SEC Form 3 filed by new insider Jiang Long
- SEC Form 3 filed by new insider Xi Youmin
- SEC Form 3 filed by new insider Wen Yilong
- SEC Form 3 filed by new insider Lu Chao